Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JENNIFER NICOLE ORNELAS

Allopathic & Osteopathic Physicians Dermatology

NPI
1013332451
CMS profile
4273715
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$11,958.52

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JENNIFER NICOLE ORNELAS

NPI 1013332451 · CMS profile ID 4273715

Allopathic & Osteopathic Physicians / Dermatology

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013332451?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JENNIFER NICOLE ORNELAS, NPI 1013332451, CMS profile ID 4273715. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013332451?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JENNIFER NICOLE ORNELAS, NPI 1013332451, CMS profile ID 4273715. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013332451?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JENNIFER NICOLE ORNELAS, NPI 1013332451, CMS profile ID 4273715, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1013332451?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $11,958.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $22.3501/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114128094 CMS
Regeneron Healthcare Solutions, Inc. $27.4801/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114128092 CMS
Janssen Biotech, Inc. $36.1901/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078322865 CMS
Lilly USA, LLC $7.6001/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135041431 CMS
ABBVIE INC. $12.2201/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105158015 CMS
ABBVIE INC. $22.1601/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105158013 CMS
Verrica Pharmaceuticals Inc. $23.6801/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118384880 CMS
ABBVIE INC. $3.0101/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105158011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $604.44 7
PY2020 $98.14 1
PY2021 $43.72 3
PY2022 $459.55 22
PY2023 $13,438.12 69
PY2024 $11,958.52 108
PY2025 $76,247.24 210

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $498,746.48 26
PY2024 Recipient $1,150.20 6
PY2024 Principal investigator $228,721.78 51
PY2023 Principal investigator $402,445.61 425
PY2022 Recipient $603.00 1
PY2022 Principal investigator $29,164.40 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,700.00 12/22/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083227
Principal investigator 1 ABBVIE INC. $34,513.35 12/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202527518
Principal investigator 1 ABBVIE INC. $10,208.39 11/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202523469
Principal investigator 1 ABBVIE INC. $17,956.00 11/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202523471
Principal investigator 1 ABBVIE INC. $18,760.20 11/05/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202522685
Principal investigator 1 SANOFI US SERVICES INC. $4,928.00 11/04/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083196
Principal investigator 1 ABBVIE INC. $30,141.45 10/09/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202514381
Principal investigator 1 SANOFI US SERVICES INC. $8,122.60 09/22/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083188
Principal investigator 1 ABBVIE INC. $25,484.55 09/04/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202509358
Principal investigator 1 ABBVIE INC. $38,977.35 08/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202503355
Principal investigator 1 SANOFI US SERVICES INC. $5,293.00 08/04/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083173
Principal investigator 1 ABBVIE INC. $30,741.15 07/02/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202495861
Principal investigator 1 SANOFI US SERVICES INC. $8,959.00 07/02/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083163
Principal investigator 1 ABBVIE INC. $26,237.25 06/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202489739
Principal investigator 1 SANOFI US SERVICES INC. $9,580.00 05/27/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083153
Principal investigator 1 ABBVIE INC. $75.00 05/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202484035
Principal investigator 1 SANOFI US SERVICES INC. $13,489.00 04/21/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083144
Principal investigator 1 ABBVIE INC. $9,320.70 04/03/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202471196
Principal investigator 1 SANOFI US SERVICES INC. $4,645.00 04/02/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083101
Principal investigator 1 Eli Lilly and Company $811.35 03/25/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889898
Principal investigator 1 ABBVIE INC. $11,952.00 03/07/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202461287
Principal investigator 1 SANOFI US SERVICES INC. $32,307.00 03/04/2025 Non-covered Recipient Entity
Integrative Skin Science And Resear
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226083092
Principal investigator 1 Eli Lilly and Company $72,636.00 02/24/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889894
Principal investigator 1 ABBVIE INC. $22,121.55 02/06/2025 Non-covered Recipient Entity
INTEGRATIVE SKIN SCIENCE
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202448897
Principal investigator 1 Eli Lilly and Company $1,471.59 01/27/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187887742
Principal investigator 1 Eli Lilly and Company $58,315.00 01/07/2025 Non-covered Recipient Entity
OSMAN DERMATOLOGY
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889896